|
Therapy
The AuRx herpes therapy is thought to work via cell-mediated immunity
(CMI). It is based on accumulating evidence that recurrent disease
is associated with a preponderance of immune regulatory T cells
[helper type 2 (Th2)] that function to downregulate the ability
of the virus specific CMI to control virus replication. The AuRx
therapy shifts the balance of the virus specific T cells to a preponderance
of protective T cells [helper type 1 (Th1) T cells] and CD8+ killer
(cytotoxic) T cells. These cells cause lysis of the virus-infected
cells. Soluble mediators are released which produce a response cascade
that includes elevated levels of interferon gamma, a stimulator
of the Th1 response which also inhibits HSV reactivation from latently
infected ganglia. The AuRx therapy also reduces the production of
the soluble mediator IL-10 which stimulates production of Th2 cells.
continue
|